文献速递痛风与晶体性关节病

加拿大安大略省老年痛风患者启动降尿酸治疗后的依从性与达标治疗基准:一项基于人群的研究

Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-06-23

该研究在加拿大安大略省纳入44,438例≥66岁新启动降尿酸治疗的痛风患者,评估12个月内血尿酸达标(<360 μmol/L)率与依从性。52.3%患者达标,从2010年45.2%升至2019年61.2%(P<0.0001);总体依从性55.3%。非布司他治疗、依从性、别嘌醇起始剂量>50 mg、秋水仙碱/口服糖皮质激素联用及风湿科医生处方与达标相关。

要点

  • 44,438例老年痛风患者中52.3%在启动降尿酸治疗12个月内血尿酸达标(<360 μmol/L)。
  • 总体依从性55.3%,达标率从2010年45.2%升至2019年61.2%(P<0.0001)。
  • 依从性(OR 5.17)与别嘌醇起始剂量>50 mg(OR 2.53)与达标关联较强。

核心结论

  • 仅52.3%患者在启动降尿酸治疗1年内达到最佳血尿酸水平,依从性欠佳但随时间改善,依从性和较高别嘌醇起始剂量与达标关联最强,研究提示痛风管理仍有改进空间及潜在策略。

研究设计与样本

  • 加拿大安大略省基于人群的回顾性队列研究,纳入2010至2019年间新 dispensing 降尿酸治疗的≥66岁痛风患者44,438例(平均年龄76.0±7.3岁,64.4%男性)。

主要发现

  • 30,057例(67.6%)患者完成至少1次血尿酸检测;52.3%患者在12个月内血尿酸达标,从2010年45.2%升至2019年61.2%(P<0.0001)。
  • 总体降尿酸治疗依从性为55.3%,且逐年改善。
  • 非布司他治疗(OR 11.40,95%CI 5.10-25.43;仅88例患者配药)与达标相关。
  • 降尿酸治疗依从性(OR 5.17,95%CI 4.89-5.47)与达标相关。
  • 别嘌醇起始剂量>50 mg(OR 2.53,95%CI 2.14-2.99)、秋水仙碱/口服糖皮质激素联用(OR 1.24,95%CI 1.14-1.34)及风湿科医生处方降尿酸治疗与达标相关。

关键数值与推荐

  • 达标治疗定义为降尿酸治疗配药后12个月内血尿酸<360 μmol/L(6 mg/dL)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to evaluate urate-lowering therapy (ULT) adherence and treatment-to-target (T2T) serum uric acid (SUA) levels among older adults with gout starting ULT. METHODS: We performed a population-based retrospective cohort study in Ontario, Canada in patients with gout aged ≥66 years newly dispensed ULT between 2010 and 2019. We defined successful T2T as patients having SUA levels <360 μmol/L (6 mg/dL) within 12 months after ULT dispensation. We also assessed adherence to ULT. Multilevel logistic regression clustered by ULT prescriber evaluated patient, physician, and prescription factors associated with reaching target SUA levels. RESULTS: Among 44,438 patients (mean ± SD age 76.0 ± 7.3 years; 64.4% male), 30,057 (67.6%) patients had ≥1 SUA test completed. Overall, 52.3% patients reached SUA target within 12 months, improving from 45.2% in 2010 to 61.2% in 2019 (P < 0.0001). ULT adherence was 55.3% overall and improved annually. Key factors associated with achieving T2T included febuxostat treatment (odds ratio [OR] 11.40, 95% confidence interval [95% CI] 5.10-25.43) (was only dispensed in 88 patients), ULT adherence (OR 5.17, 95% CI 4.89-5.47), allopurinol starting doses >50 mg (OR 2.53, 95% CI 2.14-2.99), colchicine/oral glucocorticoids co-prescription (OR 1.24, 95% CI 1.14-1.34), and ULT prescription from a rheumatologist. CONCLUSION: Only 52.3% of patients achieved an optimal SUA level within 1 year of ULT initiation. ULT adherence was suboptimal, although improving over time. ULT adherence and higher allopurinol starting doses had the strongest associations of achieving a target SUA level. This study highlights room for improvement in gout management and potential strategies to address care gaps.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kwok TSH, Kuriya B, Hawker G, et al. Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study. Arthritis Care Res (Hoboken). 2024. PMID: 38831665. doi:10.1002/acr.25380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。